Carbohydrate (i.e., Saccharide Radical Containing) Doai Patents (Class 514/23)
  • Patent number: 11040049
    Abstract: The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: June 22, 2021
    Assignee: Glycom A/S
    Inventors: Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
  • Patent number: 11040050
    Abstract: This invention relates generally to compositions and methods for preventing or treating mast cell mediated visceral pain.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 22, 2021
    Assignee: Glycom A/S
    Inventors: Louise Kristine Vigsnæs, Bruce McConnell, Emma Elison
  • Patent number: 11026959
    Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2?-fucosyllactose (2?-FL) and lacto-N-neotetraose (LNnT).
    Type: Grant
    Filed: February 14, 2018
    Date of Patent: June 8, 2021
    Assignee: Glycom A/S
    Inventors: Thierry Hennet, Bruce McConnell, Emma Elison, Louise Kristine Vigsnæs
  • Patent number: 11020447
    Abstract: Disclosed herein are methods for treating type II diabetes mellitus. In particular, the present invention relates to methods of using an extract of Hedychium coronarium Koenig and a blood glucose reduction agent, to synergistically reduce the blood glucose level of the subject having type II diabetes mellitus.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: June 1, 2021
    Assignee: VITNOVO, INC.
    Inventors: Pei-Ran Wang, Rey-Yuh Wu, Yu-Yuan Wu, Lung-Yu Kuan, Klim King
  • Patent number: 11020412
    Abstract: The present invention relates to solid oral pharmaceutical compositions comprising amorphous dapagliflozin. The invention further relates to a process for the preparation of the said pharmaceutical compositions. The said compositions are administered orally for the treatment of diabetes mellitus. The said compositions provide the desired immediate release of dapagliflozin and were found to be stable under accelerated conditions.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 1, 2021
    Assignee: INVENTIA HEALTHCARE LIMITED
    Inventors: Vaibhavi Shah, Vijayendrakumar Redasani, Anant Ghongade
  • Patent number: 11020351
    Abstract: The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 1, 2021
    Assignee: HETERO LABS LIMITED
    Inventors: Parthasaradhi Reddy Bandi, Khadgapathi Podile, Sunil Deviprasad Tiwari, Srinivasa Rao Gella
  • Patent number: 11007172
    Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.
    Type: Grant
    Filed: August 29, 2017
    Date of Patent: May 18, 2021
    Assignees: NIIGATA UNIVERSITY, MITSUBISHI TANABE PHARMA CORPORATION
    Inventor: Tohru Minamino
  • Patent number: 10987338
    Abstract: The present disclosure provides a composition of artesunate, a process of preparing the same, and a method of treatment.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: April 27, 2021
    Inventors: Ming Zhao, Li-Ming Zhou
  • Patent number: 10980822
    Abstract: Provided is a pharmaceutical composition comprising an antidiabetic agent and an antihypertensive agent as active ingredients.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: April 20, 2021
    Assignee: AUTOTELIC BIO INC.
    Inventor: Tae-Hun Kim
  • Patent number: 10976322
    Abstract: A galactose oral composition having galactose, an antioxidant and a buffer. The galactose oral composition contains 1%-80% by weight of galactose. The antioxidant is selected from Vitamin A, Vitamin C, Vitamin E, Ethylenediaminetetraacetic acid (EDTA), sodium bisulfite, flavonoids, polyphenols, Diethylenetriaminepentaacetic acid (DTPA), and NTA-Nitrilotriacetate acid (NTA). The buffer is selected from ascorbic acid buffer, citrate buffer, phosphate buffer, acetate buffer, carbonate buffer, and triethanolamine buffer. The galactose oral composition can be applied to detect individual galactose metabolic ability to assess liver function.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: April 13, 2021
    Assignee: AVALON HEPAPOC LIMITED
    Inventors: Oliver Yoa-Pu Hu, Ping Yang, Cheng-Huei Hsiong
  • Patent number: 10952989
    Abstract: The present invention is drawn to methods for effecting weight loss, e.g. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 23, 2021
    Assignee: Novartis AG
    Inventors: Deborah Lynn Keefe, Qing Shao
  • Patent number: 10945975
    Abstract: Provided herein are compositions and methods for preventing central nervous system oxygen toxicity in a subject.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: March 16, 2021
    Assignee: University of South Florida
    Inventors: Csilla Ari D'Agostino, Dominic Paul D'Agostino, Jay B. Dean
  • Patent number: 10889609
    Abstract: The present invention relates to a mannitol-based amphipathic compound, a method of preparing the same, a method of extracting, solubilizing, stabilizing or crystallizing a membrane protein using the compound, and a method of analyzing a structure of the membrane protein under an electron microscope using the compound. When the mannitol-based compound according to the present invention is used, the membrane protein can be stably stored in an aqueous solution for a prolonged period of time and thus can be applied to analysis of functions and structures thereof. Since the analysis of the structures and functions of the membrane protein is one of the fields of most interest in biology and chemistry currently, and more than half of new drugs currently in development are targeting membrane proteins, the present invention is applicable to research on the structures of membrane proteins closely related to the development of the new drugs.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: January 12, 2021
    Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS
    Inventors: Pil Seok Chae, Hazrat Hussain
  • Patent number: 10864224
    Abstract: The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: December 15, 2020
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs, David Paul Kronlage
  • Patent number: 10857168
    Abstract: This invention relates to a method and composition for modulating the microbiota in the gastro-intestinal tracts of non-infant humans who are carriers of the human fucosyltransferase 2 (FUT2) genetic mutation.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: December 8, 2020
    Assignee: GLYCOM A/S
    Inventors: Bruce McConnell, Louise Kristine Vigsnæs
  • Patent number: 10851367
    Abstract: The present application provides compounds, compositions, uses thereof for the treatment of diseases, conditions and/or disorders, and uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: December 1, 2020
    Assignees: Pfizer Inc., The Regents of the University of California
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Aaron Thuma, Jennifer A. Doudna, Romain Rouet
  • Patent number: 10836786
    Abstract: Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyOphenyl)-2-ethoxy-6-(methylhydroxyl) tetrahydro-2H-pyran-3,4,5-triol and a preparation method therefor. The advantages thereof lie in that an intermediate can be highly purified to obtain a sample with a purity of 99.3% or more, which has an important significance for improving the quality of the dapagliflozin, and the preparation process is simple and suitable for industrial production.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: November 17, 2020
    Assignee: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    Inventors: Xiang Li, Jun Yu, Haizhou Yu, Jinjia Wang, Lei He, Zuyin Du
  • Patent number: 10829509
    Abstract: Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: November 10, 2020
    Assignee: OPKO Pharmaceuticals, LLC
    Inventors: Tahir Ahmed, Arie Gutman, Irina Fedotev, Igor Rukhman, Olga Grossman
  • Patent number: 10800811
    Abstract: Object of the invention is a synthetic peptide, in particular a synthetic peptide to be used as medicament, in particular to be used in the treatment of neurodegenerative diseases and Amyotrophic Lateral Sclerosis (ALS), and compositions comprising such synthetic peptide. Furthermore, the invention concerns processes for the preparation of said synthetic peptide.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: October 13, 2020
    Assignees: Dip. di Scienze Biomediche e Biotecnologiche, Dip.di Scienze Biologiche, Geologiche e Ambientali
    Inventors: Angela Anna Messina, Vito Nicola De Pinto, Andrea Magri′, Simona Reina, Francesca Maria Guarino
  • Patent number: 10772900
    Abstract: The invention includes a method of treating or preventing a Staphylococcus infection in a mammal or avian species in need thereof. The methods comprise administering to the mammal or avian species a therapeutically effective amount of fosmidomycin. In certain embodiments, the methods treat or prevent a drug-resistant Staphylococccus infection.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 15, 2020
    Assignee: The Trustees of The University of Pennsylvania
    Inventors: Daniel P. Beiting, Ana M. Misic, Shelly C. Rankin
  • Patent number: 10765697
    Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 8, 2020
    Assignee: L & F RESEARCH LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10743542
    Abstract: In one aspect, the present disclosure belongs to the new material field and can be used to produce atomic-state fluid iodine by iodine atom rearrangement occurring in the pseudo-critical reaction system. In one aspect, the atomic-state fluid iodine has a specific gravity of about 3.8-4.0 g/mL and maintains stable physical state under 10-100 C and light environment without sublimation or decomposition.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 18, 2020
    Assignee: CHINESE ACADEMY OF AGRICULTURAL ENGINEERING PLANNING & DESIGN
    Inventors: Shikui Wang, Xuefang Hu, Zhimin Zhang, Liang Liang, Zhiqing Tian
  • Patent number: 10736973
    Abstract: Provided are methods and formulations for imaging at least one body region of a subject, employing a glucose analog resistant or inactive to phosphrylation, or which is not a substrate for hexokinase.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 11, 2020
    Assignee: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
    Inventors: Gil Navon, Michal Rivlin, Ilan Tsarfaty
  • Patent number: 10721955
    Abstract: An energy composition includes a methylated xanthine, a choline derivative, and at least one flavorant in a sufficient amount to render the energy composition palatable. The energy composition may also include vitamins, amino acids, enzymes, preservatives, and the like.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: July 28, 2020
    Assignee: International IP Holdings LLC
    Inventor: Manoj Bhargava
  • Patent number: 10716802
    Abstract: This disclosure relates to compositions including formulated sucralfate or other aluminum-crosslinked sulfated agents for the modulation of nutrient absorption through the intestinal lining as well as methods for the manufacture of and the use of these compounds for treating disorders requiring a modulation of certain nutrients to the body including diabetes type II and clinical obesity.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 21, 2020
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Jeffrey M. Karp, Yuhan Lee, Ali Tavakkoli, Tarawatie E. Deelman
  • Patent number: 10717789
    Abstract: A polydisperse inulin product has a factor L, defined as a ratio S/D, wherein: S equals the sum of the compounds GF2, F3, and F4 in the inulin product, expressed in wt. % on total carbohydrates; D equals [(Fi/Gi)+1], wherein Fi is the amount of inulin-related fructose in the inulin product, Gi is the amount of inulin-related glucose in the inulin product, whereby Fi and Gi are expressed in wt. % on total carbohydrates, wherein the value of L lies between 2.0 and 3.0 and wherein between 3 and 20 wt. % on total carbohydrates of the inulin product is: GFn compounds wherein n is 10 or greater, and/or Fm compounds wherein m is 11 or greater.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: July 21, 2020
    Assignee: TIENSE SUIKERRAFFINADERIJ N.V.
    Inventor: Linda Mertens
  • Patent number: 10716778
    Abstract: The present disclosure relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular, in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: July 21, 2020
    Assignee: Veijlen
    Inventors: Hubert Jean-Marie Francois Gillessen, Christian Rebiere
  • Patent number: 10682368
    Abstract: Provided are methods of treating feline Coronavirus infections using carbanucleoside compounds having a 1?-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl) substituent, or a pharmaceutically acceptable salt thereof. An exemplary compound is (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: June 16, 2020
    Assignees: GILEAD SCIENCES, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michel Joseph Perron, Niels C. Pedersen
  • Patent number: 10675287
    Abstract: The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: June 9, 2020
    Assignee: Bial-Portela & CA S.A.
    Inventors: José Luís de Almeida, Patrício Manuel Vieira Araújo Soares da Silva
  • Patent number: 10668086
    Abstract: The invention relates to a capsule consisting of a shell and a filling, which contains plant sterol ester and/or plant stanol ester and emulsifier. The capsule is suitable for lowering serum LDL cholesterol level.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: June 2, 2020
    Assignee: RAISIO NUTRITION LTD
    Inventors: Päivi Kuusisto, Ingmar Wester, Leena Koponen, Jari Ekblom, Jouni Niemela
  • Patent number: 10647737
    Abstract: A synthetic charged glycolipid is described comprising a sulfated saccharide group covalently linked to the tree sn-1 hydroxyl group of the glycerol backbone of an archaeal core lipid via a beta linkage. The synthetic charged glycolipids include compounds of formula I wherein n is 0 or 1; R is hydrogen or hydroxyl; and Y is hydrogen or a sulfate group, at least one Y being a sulfate group; and including pharmaceutically acceptable salts thereof. The sulfated glycolipid produces stable archaeosomes at a mol % ratio of from 100:0 to 30:70 (sulfated glycolipid:uncharged glycolipid) and which induce a protective immune response, including CD8+ and CD4+ T cell responses. Archaeosomes comprising the sulfated glycolipids described have desirable adjuvant properties, particularly when mixed with uncharged glycolipid at a mol % ratio of about 50:50.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: May 12, 2020
    Assignee: National Research Council of Canada
    Inventors: Dennis M. Whitfield, G. Dennis Sprott, Lakshmi Krishnan
  • Patent number: 10633372
    Abstract: The present invention relates to an improved process for the preparation of amorphous (1S)-1,5-anhydro-1-[3-[[5 -(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol compound of formula-1, represented by the following structural formula.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: April 28, 2020
    Assignee: MSN LABORATORIES PRIVATE LIMITED
    Inventors: Srinivasan Thirumalai Rajan, Sajja Eswaraiah, Chakilam Nagaraju, Achampeta Kodanda Ramprasad, Peri Seetha Rama Sarma, Boge Rajesham
  • Patent number: 10624859
    Abstract: Disclosed in certain embodiments is a system and method of providing a dronabinol oral solid dosage form with increased stability.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: April 21, 2020
    Assignee: Rhodes Technologies
    Inventor: Robert J. Kupper
  • Patent number: 10624875
    Abstract: The invention relates to methods and compositions for treating schizophrenia or bipolar disorder (in particular, mania) by using a combination of a synaptic vesicle protein 2A (SV2A) inhibitor and an antipsychotic or their pharmaceutically acceptable salts, hydrates, solvates, polymorphs thereof. In some embodiments, the methods and the compositions are for treating one or more positive and/or negative symptoms, as well as cognitive impairment, associated with schizophrenia or bipolar disorder (in particular, mania).
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: April 21, 2020
    Assignee: The Johns Hopkins University
    Inventors: Michela Gallagher, Ming Teng Koh
  • Patent number: 10617694
    Abstract: There is provided for novel therapy of sleep apnea that involves administering the drug sultiame to the patient.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: April 14, 2020
    Inventors: Jan Hedner, Ludger Grote, Kaj Stenlöf
  • Patent number: 10576137
    Abstract: The invention relates to methods of producing, and compositions comprising, an isolated alpha (2?8) or (2?9) oligosialic acid derivative bearing a non-reducing end enriched for one or more de-N-acetyl residues and resistant to degradation by exoneuraminidase. A representative production method involves: (i) treating an alpha (2?8) or (2?9) oligosialic acid precursor having a reducing end and a non-reducing end with sodium borohydride under conditions for de-N-acetylating the non-reducing end; and (ii) isolating alpha (2?8) or (2?9) oligosialic acid derivative having one or more de-N-acetylated residues and a non-reducing end that is resistant to degradation by exoneuraminidase. Isolated alpha (2?8) or (2?9) oligosialic acid derivatives that comprise a non-reducing end de-N-acetyl residue are provided, as well as antibodies specific for the derivatives, compositions comprising the derivatives, kits, and methods of use including protection against and detection of E. coli K1 and N.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: March 3, 2020
    Assignee: Children's Hospital Research Center at Oakland
    Inventors: Gregory R. Moe, Brent T. Hagen
  • Patent number: 10568919
    Abstract: The present invention discloses a composition and use. The composition comprises hemp seed oil and algal oil with a mass ratio of (20˜60):(30˜70). After a large number of screening studies on concerted application, the present inventors found that the composition has synergistic effects, specifically, it has significant inhibitory effects on weight gain of animal model rats for hyperlipidemia, can significantly increase the hypolipidemic efficacy, and has an anti-oxidation effect. In addition, the composition of the present invention has efficacies of improving learning and memory abilities, improving constipation, and protecting the liver. Medicaments and functional food made from the composition of the present invention are simple in production process, stable in product quality, clear in functional factor, prominent in health care efficacy, low in administration dosage, safe in use, without toxic and side effects, and are suitable for consumption of the general population.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: February 25, 2020
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Zehua Chen, Jialing Ning, Chung Wah Ma, Yiting Yang, Fang Ma
  • Patent number: 10561623
    Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: February 18, 2020
    Assignee: The Charlotte Mecklenburg Hospital Authority
    Inventor: Qi Long Lu
  • Patent number: 10556877
    Abstract: The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: February 11, 2020
    Assignee: Glenmark Life Sciences Limited
    Inventors: Shekhar Bhaskar Bhirud, Kumar Hari Bhushan, Raghu Ram Suraparaju, Nandkumar Gaikwad, Sharad Gore, Rajendra Jagdhane, Mandar Kulkarni
  • Patent number: 10538547
    Abstract: The present invention provides a mangiferin-6-O-calcium salt and a preparation process thereof. In addition, use of the mangiferin-6-O-calcium salt as defined in claim 1 as an intermediate in the preparation of a mangiferin-6-O-berberine salt is also provided.
    Type: Grant
    Filed: December 25, 2018
    Date of Patent: January 21, 2020
    Assignee: CHANGZHOU DEZE MEDICAL SCIENCE CO., LTD
    Inventors: Houlei Teng, Wei Wu
  • Patent number: 10533032
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: January 14, 2020
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • Patent number: 10525078
    Abstract: A solid dialysis A agent is provided, which is to be used in preparing a bicarbonate dialysis fluid, wherein: the solid dialysis A agent contains glucose, acetic acid and an acetate salt; at least a part of a mixture of the acetic acid with the acetate salt is an alkali metal diacetate; and the acetic acid/acetate salt molar ratio is adjusted to 1/0.5 to 1/2. This solid dialysis A agent makes it possible to prepare a bicarbonate dialysis fluid which has a total acetate ion concentration of 2 to less than 6 mEq/L. Further, the dialysis A agent exhibits excellent stability of ingredients and a reduced acetic acid odor.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: January 7, 2020
    Assignee: Tomita Pharmaceutical Co., Ltd.
    Inventors: Michiko Myose, Hiroshi Noguchi, Junya Kikuishi, Hideyuki Aoyama, Mina Hashimoto, Yusuke Yoshimoto
  • Patent number: 10500175
    Abstract: The present invention discloses anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide; and R is selected from the group consisting of: OR?, N(R?)2, C(O)R??, C1-C6 alkyl, C6-C12 aryl, C1-C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal; where R? represents H, alkali metal, C1-C6 alkyl, C6-C12 aryl or C(O)R??, R? represents H, C1-C6 alkyl, or C6-C12 aryl, and R?? represents H, C1-C20 alkyl or C6-C12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a hexokinase inhibitor.
    Type: Grant
    Filed: December 26, 2017
    Date of Patent: December 10, 2019
    Assignee: KODISCOVERY, LLC
    Inventor: Young Hee Ko
  • Patent number: 10478446
    Abstract: Polycystic kidney disease is a cystic genetic disorder of the kidneys. Recent identification of signaling cascades de-regulated in PKD has led to the initiation of several clinical trials, but an effective therapy is still lacking. A new therapeutic paradigm is capable of improving the proliferation rate and cystic kidney volume in PKD.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: November 19, 2019
    Assignees: FONDAZIONE CENTRO SAN RAFFAELE OFFICE OF BIOTECHNOLOGY TRANSFER, FONDAZIONE TELETHON
    Inventors: Alessandra Boletta, Marco Chiaravalli, Isaline Severine Marie-Josephe Rowe
  • Patent number: 10457671
    Abstract: The invention relates to a new crystalline form of Canagliflozin of formula I, with its systematic name (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl) methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol5 and a method of its preparation.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: October 29, 2019
    Assignee: Zentiva k.s.
    Inventors: Josef Zezula, Peter Babiak, Ondrej Dammer
  • Patent number: 10391044
    Abstract: The present disclosure provides low water dentifrice compositions comprising an effective amount of a zinc ion source, a stannous ion source, a polyphosphate and an acid in a calcium pyrophosphate base. The acid lowers the pH of the composition to enable stabilization of the metal ions and extend shelf-life of the composition.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: August 27, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Kavita Vemishetti, Linh Fruge, Michael Prencipe
  • Patent number: 10369163
    Abstract: Compositions and foods which contain (1) histidine and (2) vitamin B6 and/or carnosine are useful for treating, improving, and recovering from fatigue.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: August 6, 2019
    Assignee: AJINOMOTO CO., INC.
    Inventors: Tetsuro Shibakusa, Mayu Sugita
  • Patent number: 10342867
    Abstract: The present invention relates to a family of carbohydrate monosulphate fatty acid esters, which contain less than 10 mole % of carbohydrate polysulphate fatty acid esters, and to a method of preparation thereof. The monosulphate carbohydrate esters according to the invention comprise one sulphate ester and at least one fatty acid and are among others useful as adjuvants for immunological products such as vaccines.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: July 9, 2019
    Assignee: LITEVAX B.V.
    Inventors: Lucas A. Th. Hilgers, Peter Paul L. I. Platenburg, Johannes F. Van Den Bosch
  • Patent number: 10327678
    Abstract: Embodiments of the invention provide analyte sensors having optimized elements and/or configurations of elements as well as methods for making and using such sensors. Typical embodiments of the invention include glucose sensors used in the management of diabetes.
    Type: Grant
    Filed: April 8, 2014
    Date of Patent: June 25, 2019
    Assignee: Medtronic MiniMed, Inc.
    Inventors: Rebecca K. Gottlieb, Rajiv Shah, Eric A. Larson, Chia Chiu
  • Patent number: 10307352
    Abstract: A composition including water, about 0.1% to about 0.4% of a 4-substituted resorcinol, an ester having at least about 25 carbon atoms, and a polymeric emulsifier is provided. The composition comprises less than about 5% by weight of oils and is substantially free of monomeric emulsifier. Methods of treating the skin are also provided.
    Type: Grant
    Filed: August 30, 2016
    Date of Patent: June 4, 2019
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Marisa DeVita Dufort, Simarna Kaur, Michael D. Southall, Ping Wen, Jeffrey M. Wu